There are 2789 resources available
96P - Real-world single institution clinical outcome study of the impact of comprehensive genomic profiling (CGP) on targeted therapy selection and cancer patient survival
Presenter: Bhaskara Reddy Madhira
Session: ePoster Display
97P - Comparative serum metabolome analysis as a diagnostic tool in concomitant rheumatic and malignant diseases
Presenter: Dorothea Marx
Session: ePoster Display
8P - The characterization of tumors associated with the antitumor activity of lenvatinib plus anti-PD-1 antibody combination therapy in a mouse syngeneic model panel
Presenter: Yoichi Ozawa
Session: ePoster Display
9P - Click Activated Protodrugs Against Cancer (CAPAC) platform enhances the safety, pharmacokinetics, and antitumor efficacy of cancer therapies in vivo
Presenter: Sangeetha Srinivasan
Session: ePoster Display
47P - Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01
Presenter: Michele Droz Dit Busset
Session: ePoster Display
48P - (BREGO) Regorafenib combined with modified m-GEMOX in patients with advanced biliary tract cancer (BTC): A phase II randomized trial
Presenter: Eric Assenat
Session: ePoster Display
49P - A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
Presenter: Nai-Jung Chiang
Session: ePoster Display
51P - Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)
Presenter: Funda Meric-Bernstam
Session: ePoster Display
52P - Assessment of futibatinib exposure–response (E–R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA)
Presenter: Antoine Hollebecque
Session: ePoster Display